NMN for Health & Longevity - Quick Reference Sheet
evipedia.ai ← Back

NMN for Health & Longevity

Created on 07/08/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 – Audit

NMN reliably raises blood levels of a key molecule cells need for energy and repair, a molecule that declines with age. Whether this delivers real health gains is uncertain: hints of better endurance and blood-sugar handling exist, but broader evidence is thin. Short-term use appears well tolerated; long-term safety and product quality remain open questions. (Full Review)

Protocol

Dose
250–900 mg/day
Some protocols extend to 1000–1200 mg/day
Timing
Morning
Consistency matters more than exact timing
Frequency
Once or twice daily
Splitting may reduce gastrointestinal symptoms at higher totals
Time to effect
NAD+ Elevation
Days–weeks
The single best-established effect
Functional Effects
4–12 weeks
Energy, endurance, metabolic markers
Peak Blood NMN
30–45 min
Rapidly cleared; NAD+ then builds over days

Benefits

Contraindications
  • Pregnancy & breastfeeding
  • Active malignancy or high cancer risk
  • Significant kidney impairment (eGFR <60 mL/min/1.73m²)
  • Active cancer therapy (chemotherapy, radiation)
    •
Key Interactions
  • Other NAD+ precursors (nicotinamide riboside, niacin, nicotinamide)
  • Methylation-sensitive drugs (methotrexate, levodopa)
  • Over-the-counter niacin / flush-inducing agents
  • Additive metabolic or vascular supplements (berberine, other NAD+ modulators)
    •

Risk & Side Effects

  • High:
  • Medium: Mild gastrointestinal & general symptoms
    •
  • Low: Methyl-group depletion & elevated homocysteine; potential kidney injury with long-term use
    •
  • Speculative: Theoretical promotion of existing cancers; unknown long-term safety
    •

Monitoring

Marker Target Why
Whole-blood NAD+ Increase from personal baseline Confirms the intervention is doing its one well-established job
Fasting glucose 70–90 mg/dL Tracks metabolic response in insulin-resistant users
HbA1c < 5.4% Captures metabolic effect over ~3 months
Homocysteine < 8 µmol/L Flags methylation strain from high nicotinamide turnover
Creatinine / eGFR eGFR > 90 mL/min/1.73m² Surveillance for the theoretical kidney concern with long-term use
hs-CRP < 1.0 mg/L Contextualizes inflammation that drives NAD+ consumption

Cadence: Baseline, first re-check at 8–12 weeks, then every 6–12 months during sustained use; more frequent kidney checks in older adults

Qualitative Assessment

  • Daytime energy and fatigue levels
  • Exercise endurance and recovery
  • Sleep quality and daytime drowsiness
  • General sense of well-being
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.